Categories: 健康心血管病

Familial Hypercholesterolemia Linked with Lower Risk of Type 2 Diabetes家族性高胆固醇血症与2型糖尿病的风险降低有关

In a cross-sectional analysis in the Netherlands, the prevalence of type 2 diabetes (T2D) among patients with familial hypercholesterolemia (FHC) was significantly lower than among unaffected relatives, with variability by mutation type. The study included all individuals (n = 63 320) who underwent DNA testing for FHC in the national Dutch screening program between 1994 and 2014. The prevalence of T2D was 1.75% in FHC patients vs 2.93% in unaffected relatives (P < .001). The adjusted prevalence of T2D in FHC, determined using multivariable regression models, was 1.44% (P < .001). The adjusted prevalence of T2D by apolipoprotein B gene vs low-density lipoprotein receptor gene was 1.91% vs 1.33%, and the prevalence for receptor-deficient vs receptor-negative mutation carriers was 1.44% vs 1.12%, respectively (P for trend <.001 in both comparisons). FHC is characterized by impaired uptake of cholesterol in peripheral tissues. Statins increase the cellular cholesterol uptake and may be associated with increased risk for type 2 diabetes mellitus. However, starting statin therapy early in people with high cholesterol genetic disorders is still warranted. Source: http://jama.jamanetwork.com/荷兰的一个横断面分析中,家族性高胆固醇血症(FHC)患者2型糖尿病(T2D)的患病率比未受影响的亲属显著降低,且随突变类型有所差异。这项研究包括了1994至2014年间荷兰国家筛查项目中所有接受DNA测试FHC的个人(N = 63 320)。FHC患者T2D的患病率为1.75%,而未受影响的亲戚为2.93%(P <0.001) 。经使用多变量回归模型校正,FHC患者T2D的患病率为1.44%(P <0.001)。 经校正的载脂蛋白B基因相对于低密度脂蛋白受体基因的T2D患病率分别为1.91%和1.33%,而受体缺陷相对于受体阴性突变携带者的T2D患病率分别为1.44%和1.12%(两项比较中趋势P <0.001)。 FHC的特征是外周组织中胆固醇的摄取受损。他汀类药物增加了细胞内胆固醇的摄取,并且可能与T2D的风险增加有关。然而,患高胆固醇遗传性疾病者及早开始他汀类药物仍然是必要的。来源:http://jama.jamanetwork.com/

hyangiu

近期博文

4:3间歇性禁食减肥效果优于每日热量限制

一项美国随机临床试验发现,对于…

2 天 ago

新型降糖药对老年二型糖尿病患者心血管病的效果比较

一项丹麦全国性队列研究提供的真…

1 周 ago

非手术与非介入疗法对腰痛的疗效

基于安慰剂对照的随机试验,一项…

2 周 ago

服用他汀类药物与肝癌及肝病进展风险降低有关

一项美国队列研究提示,服用他汀…

2 周 ago

颈动脉斑块的临床意义及其与年龄和性别的关系

一项美国队列研究提示,在没有临…

3 周 ago

用植物油取代黄油可提高生存率

一项基于美国人群的前瞻性队列研…

4 周 ago

This website uses cookies.